Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Due Diligence who wrote (111655)	3/24/2004 12:36:31 PM
From: rrufff	Read Replies (1) \| Respond to of 208838

IMX - 11.15 + .69 11.74 HOY - in forefront of bomb detection but also cancer and medicated stents. Implant Sciences Corporation Appears on National Fox News Channel's 'Fox & Friends'; Live On-Air Demonstration of Hand-Held Explosives Detection Device Business Wire - March 24, 2004 11:50 WAKEFIELD, Mass., Mar 24, 2004 (BUSINESS WIRE) -- Implant Sciences Corporation's (AMEX: "IMX", "IMX.WS"), "Quantum Sniffer" bomb detection device garnered national media attention today. CEO Dr. Anthony Armini and his bomb detection team were seen demonstrating the benefits of the "Quantum Sniffer" this morning (6:45 AM) on "Fox & Friends" (FOX), the 24-hour cable news network. Fox's Judge Andrew Napolitano and anchor Juliet Huddy talked to Dr. Armini and saw first hand how the Quantum Sniffer's Laser IMS technology may provide decided advantages in the detection of explosives. The national audience also viewed how the non-contact feature of the Quantum Sniffer may enable the rapid inspection of people as well as various items under simulated security checkpoint conditions. "I would like to thank the FOX News Channel for providing Implant the opportunity to demonstrate our unique explosives detection device on national television," commented Dr. Anthony J. Armini, CEO of Implant Sciences Corporation. "Given the concern over terrorist bombings, we believe it is of paramount importance that cutting edge technology, such as our Quantum Sniffer, be made known and available to government and commercial entities for incorporation into their respective security strategies. This broadcast came at an opportune time as we kick-off our previously announced five city road show, commencing in Boca Raton on Thursday, March 25, 2004." Anyone who would like a personal viewing of the interview on CD may request one by sending a message to mailbox@implantsciences.com. Anyone who would like information on the scheduled road show may contact the Aurelius Consulting Group at 407-644-4256. A complete road show schedule may be found at www.runonideas.com/imxroadshow.asp. About Implant Sciences Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for national security, industry, and medicine. Under development is a portable trace explosives detection device to identify explosives, narcotics and other toxic materials. Implant has received development grants from the US Army, Navy and Air Force, and, signed a cooperative R&D agreement with the Transportation Security Administration, which facilitates equipment evaluation and new government contracts. Using its proprietary ion implantation and thin film coating technologies, Implant also manufactures and markets radioactive and non-radioactive products for medical use. Implant derives revenues from its radioactive seeds for treating prostate cancer that are distributed throughout the US by its direct sales force. Implant is also developing brachytherapy products for the treatment of breast, eye, and other cancers. Additionally, Implant modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby increasing the life of the implants. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. SOURCE: Implant Sciences Corporation Investor: Aurelius Consulting Group: Dave Gentry, 407-644-4256 dave@aurcg.com www.runonideas.com or Implant Sciences Corporation: David C. Volpe, 508-523-3141 dvolpe@implantsciences.com www.implantsciences.com or Media: The Investor Relations Group Mike Graff or Janet Vasquez 212-825-3210 Customize your Business Wire news & multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com.